N-terminal selective conjugation method widens the therapeutic window of antibody–drug conjugates by improving tolerability and stability

Min Ji Koa ABL Bio Inc., Seongnam-si, Republic of KoreaView further author information

Daehae Songa ABL Bio Inc., Seongnam-si, Republic of Korea

Juhee Kima ABL Bio Inc., Seongnam-si, Republic of KoreaView further author information

Jae Yong Kimb Global Support Center, Samsung Biologics, Incheon, Republic of KoreaView further author information

Jaehyun Eoma ABL Bio Inc., Seongnam-si, Republic of KoreaView further author information

Byungje Sunga ABL Bio Inc., Seongnam-si, Republic of KoreaView further author information

Yong-Gyu Sona ABL Bio Inc., Seongnam-si, Republic of KoreaView further author information

Young Min Kimc BIO Business Division, Reyon Pharmaceutical Co., Ltd, Seoul, Republic of KoreaView further author information

Sang Hoon Leea ABL Bio Inc., Seongnam-si, Republic of KoreaView further author information

Weon-Kyoo Youa ABL Bio Inc., Seongnam-si, Republic of KoreaView further author information

Jinwon Junga ABL Bio Inc., Seongnam-si, Republic of KoreaCorrespondence[email protected]

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.